Isturisa effective in treating rare Cushing’s disease
pharmafile | April 1, 2022 | News story | Medical Communications |
Recordati Rare Diseases has announced the publication of positive results from the Phase III LNC 4 study, confirming the efficacy and safety of Isturisa (osilodrostat), for the treatment of Cushing’s disease.
In the Phase III trial, the oral therapy Isturisa provided rapid and sustained control of cortisol secretion in the majority of patients throughout the 48-week core phase of the study.
Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome, a rare and debilitating condition of hypercortisolism that is most commonly caused by a pituitary adenoma (Cushing’s disease).
“These results show convincingly that osilodrostat is an effective treatment for Cushing’s disease,” said Peter J Snyder MD, Professor of Medicine at the University of Pennsylvania. “Osilodrostat rapidly lowered cortisol excretion to normal in most patients with Cushing’s disease and maintained normal levels throughout the core phase of the study. Importantly, this normalisation was accompanied by improvements in cardiovascular and metabolic parameters, which increase morbidity and mortality in Cushing’s disease.”
Cushing’s syndrome is a rare disorder caused by chronic exposure to excess levels of cortisol from either an exogenous (such as medication) or an endogenous source, that is, a source originating in the body.
Cushing’s disease occurs when your body makes too much of the hormone cortisol over a long period of time. It is the most common cause of endogenous Cushing’s syndrome, and arises as a result of a tumour of the pituitary gland. There is often a delay in diagnosing Cushing’s syndrome, which consequently leads to a delay in treating patients.
Patients who are exposed to excess levels of cortisol for a prolonged period have increased comorbidities associated with the cardiovascular and metabolic systems, which consequently increase the risk of mortality.
Ana Ovey
